Stephen N. Davis
Research Subjects
Research Interests
Stephen N. Davis has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Donna B. Tate
University of Maryland, Baltimore, MD
12 shared publicationsMaka S. Hedrington
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
12 shared publicationsLisa M. Younk
University of Maryland, Baltimore, MD
8 shared publicationsLisa M Younk
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
7 shared publicationsElizabeth Mary Lamos
A Division of Endocrinology, Diabetes and Metabolism, University of Maryland School of Medicine , Baltimore , MD , USA
5 shared publicationsMaia Mikeladze
University of Maryland, Baltimore, MD
5 shared publications
Latest Publications
- 14 August 2026
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 27 (13) , 1375-1378
Once-weekly insulins: a paradigm shift in the management of type 2 diabetes?
1. Despite the availability of highly effective non-insulin glucose-lowering therapies, a substantial proportion of individuals with T2D ultimately require basal insulin to achieve and maintain gly...
- 14 August 2026
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 27 (13) , 1375-1378
Once-weekly insulins: a paradigm shift in the management of type 2 diabetes?
1. Despite the availability of highly effective non-insulin glucose-lowering therapies, a substantial proportion of individuals with T2D ultimately require basal insulin to achieve and maintain gly...
- 12 December 2024
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- p. 1-10
Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what’s new?
IntroductionType 1 diabetes is a chronic autoimmune condition characterized by the selective destruction of insulin-producing beta cells in the pancreas. The etiology of T1D is multifactorial, with a combination of genetic susceptibility and environmental triggers believed to underlie beta-cell destruction. Preserving and prolonging beta-cell function in T1D is a pivotal therapeutic objective that can mitigate disease progression and improve glycemic control.Areas coveredInsulin secretagogues have long been used in the management of type 2 diabetes, but do not have a significant beneficial effect in individuals with long-standing type 1 diabetes. Enhancement of beta-cell function early in the course of type 1 diabetes may offer important benefits in glycemic control and reduced hypoglycemia risk. Glucagon-like peptide-1 receptor agonists, glucokinase activators, free fatty acid receptor agonists, and glimins are drug classes which may offer benefit in enhancing insulin secretion in individuals with type 1 diabetes.Expert opinionDrugs which enhance insulin secretion in individuals may offer clinical benefits to individuals with type 1 diabetes. However, the lack of beta-cell capacity introduces a challenge without regeneration of insulin-producing cells. Stem cell therapies combined with regulation of islet autoimmunity may offer the best prospect of increased insulin secretion in individuals with T1D.
- 12 December 2024
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- p. 1-10
Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what’s new?
IntroductionType 1 diabetes is a chronic autoimmune condition characterized by the selective destruction of insulin-producing beta cells in the pancreas. The etiology of T1D is multifactorial, with a combination of genetic susceptibility and environmental triggers believed to underlie beta-cell destruction. Preserving and prolonging beta-cell function in T1D is a pivotal therapeutic objective that can mitigate disease progression and improve glycemic control.Areas coveredInsulin secretagogues have long been used in the management of type 2 diabetes, but do not have a significant beneficial effect in individuals with long-standing type 1 diabetes. Enhancement of beta-cell function early in the course of type 1 diabetes may offer important benefits in glycemic control and reduced hypoglycemia risk. Glucagon-like peptide-1 receptor agonists, glucokinase activators, free fatty acid receptor agonists, and glimins are drug classes which may offer benefit in enhancing insulin secretion in individuals with type 1 diabetes.Expert opinionDrugs which enhance insulin secretion in individuals may offer clinical benefits to individuals with type 1 diabetes. However, the lack of beta-cell capacity introduces a challenge without regeneration of insulin-producing cells. Stem cell therapies combined with regulation of islet autoimmunity may offer the best prospect of increased insulin secretion in individuals with T1D.
- 3 August 2023
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 24 (15) , 1-3
How close are we to personalized pharmacotherapies and innovative technology for type 1 diabetes management?
- 3 August 2023
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 24 (15) , 1-3
How close are we to personalized pharmacotherapies and innovative technology for type 1 diabetes management?
- 19 January 2023
- Published by Elsevier
- p. 569-574
Diabetic autonomic dysfunction
- 2 January 2023
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 27 (1) , 31-40
Type 1 diabetes: key drug targets and how they could influence future therapeutics
: Despite significant strides made in the management of T1DM, standard management is still insulin analogue therapy. Some non-insulin therapies traditionally reserved for the treatment of T2DM have...
- 2 January 2023
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 27 (1) , 31-40
Type 1 diabetes: key drug targets and how they could influence future therapeutics
: Despite significant strides made in the management of T1DM, standard management is still insulin analogue therapy. Some non-insulin therapies traditionally reserved for the treatment of T2DM have...
- 28 June 2022
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 23 (11) , 1259-1271
The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes
Type 2 diabetes mellitus is a complex progressive disease leading to chronic hyperglycemia due to insulin resistance and pancreatic beta-cell failure. Intensification of treatment regimens is often...
- 28 June 2022
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 23 (11) , 1259-1271
The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes
Type 2 diabetes mellitus is a complex progressive disease leading to chronic hyperglycemia due to insulin resistance and pancreatic beta-cell failure. Intensification of treatment regimens is often...
- 15 September 2021
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 16 (6) , 281-293
Nocturnal hypoglycemia in type 1 and type 2 diabetes: an update on prevalence, prevention, pathophysiology and patient awareness
Despite considerable progress in diabetes treatment, prevalence of nocturnal hypoglycemia in type 1 diabetes mellitus (T1DM) and advanced insulin treated type 2 diabetes mellitus (T2DM) remains hig...
- 15 September 2021
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 16 (6) , 281-293
Nocturnal hypoglycemia in type 1 and type 2 diabetes: an update on prevalence, prevention, pathophysiology and patient awareness
Despite considerable progress in diabetes treatment, prevalence of nocturnal hypoglycemia in type 1 diabetes mellitus (T1DM) and advanced insulin treated type 2 diabetes mellitus (T2DM) remains hig...
- 21 August 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (16) , 2181-2198
Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes
Sodium−glucose cotransporter (SGLT) 2 inhibitors reduce glucose reabsorption in the kidney, increase glucosuria, and improve glycemia. Besides glycemic efficacy, the class also lowers risk of cardi...
- 21 August 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (16) , 2181-2198
Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes
Sodium−glucose cotransporter (SGLT) 2 inhibitors reduce glucose reabsorption in the kidney, increase glucosuria, and improve glycemia. Besides glycemic efficacy, the class also lowers risk of cardi...
- 27 May 2021
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 14 (9) , 1081-1089
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) offer a unique opportunity to simultaneously address various comorbid associated conditions and phenotypic presentations of polycystic ovary syndrome (PCOS) as these agents improve insulin sensitivity, reduce cardiovascular disease (CVD) risk, result in weight loss, and improve nonalcoholic fatty liver disease. Areas covered: The authors describe trials conducted during the last 5 years and provide an update on exenatide and liraglutide use in PCOS women. Information from the studies investigating GLP-1 RAs effects on reducing CVD risk in PCOS is also presented. Expert opinion: Exenatide and liraglutide are good options for the treatment of PCOS when used alone or in combination with metformin. Especially strong consideration should be given to GLP-1 RAs when developing treatment strategies for PCOS women who are overweight or obese, glucose intolerant, have CVD or its attendant risk factors, and/or are seeking treatment for infertility.
- 27 May 2021
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 14 (9) , 1081-1089
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) offer a unique opportunity to simultaneously address various comorbid associated conditions and phenotypic presentations of polycystic ovary syndrome (PCOS) as these agents improve insulin sensitivity, reduce cardiovascular disease (CVD) risk, result in weight loss, and improve nonalcoholic fatty liver disease. Areas covered: The authors describe trials conducted during the last 5 years and provide an update on exenatide and liraglutide use in PCOS women. Information from the studies investigating GLP-1 RAs effects on reducing CVD risk in PCOS is also presented. Expert opinion: Exenatide and liraglutide are good options for the treatment of PCOS when used alone or in combination with metformin. Especially strong consideration should be given to GLP-1 RAs when developing treatment strategies for PCOS women who are overweight or obese, glucose intolerant, have CVD or its attendant risk factors, and/or are seeking treatment for infertility.
- 22 April 2021
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 14 (7) , 837-852
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Introduction: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are significant non-communicable diseases that often affect individuals concurrently. In individuals with both T2DM and NAFLD, there is evidence that anti-diabetic therapies may demonstrate potential combined beneficial metabolic and reduced hepatic inflammatory effects. Areas covered: A PubMed and Google Scholar search was performed to find relevant literature. Included studies focused on individuals with T2DM and NAFLD receiving anti-diabetic treatments including bariatric surgery, insulin sensitizers, incretin mimetics, and SGLT2 inhibitors. Additional articles highlight investigational treatments. Expert opinion: In individuals with T2DM and NAFLD, 5–10% weight loss or bariatric surgery if unable to lose weight or maintain weight loss are appropriate. GLP-1 receptor agonists and SGLT2 inhibitors result in weight loss, appear safe and may provide beneficial hepatic outcomes. Whether their effects are related to favorable weight changes or intrinsic hepatic effects is unclear. Thiazolidinediones have advantageous anti-hyperglycemic and hepatic effects but individuals must be monitored for weight gain and edema. Metformin and DPP-4 inhibitor beneficial hepatic effects remain debated. There are opportunities to standardize markers and imaging of NAFLD. Studies powered to evaluate the possible cardiovascular benefits of anti-diabetic therapies in individuals with T2DM and NAFLD are needed.
- 22 April 2021
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 14 (7) , 837-852
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Introduction: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are significant non-communicable diseases that often affect individuals concurrently. In individuals with both T2DM and NAFLD, there is evidence that anti-diabetic therapies may demonstrate potential combined beneficial metabolic and reduced hepatic inflammatory effects. Areas covered: A PubMed and Google Scholar search was performed to find relevant literature. Included studies focused on individuals with T2DM and NAFLD receiving anti-diabetic treatments including bariatric surgery, insulin sensitizers, incretin mimetics, and SGLT2 inhibitors. Additional articles highlight investigational treatments. Expert opinion: In individuals with T2DM and NAFLD, 5–10% weight loss or bariatric surgery if unable to lose weight or maintain weight loss are appropriate. GLP-1 receptor agonists and SGLT2 inhibitors result in weight loss, appear safe and may provide beneficial hepatic outcomes. Whether their effects are related to favorable weight changes or intrinsic hepatic effects is unclear. Thiazolidinediones have advantageous anti-hyperglycemic and hepatic effects but individuals must be monitored for weight gain and edema. Metformin and DPP-4 inhibitor beneficial hepatic effects remain debated. There are opportunities to standardize markers and imaging of NAFLD. Studies powered to evaluate the possible cardiovascular benefits of anti-diabetic therapies in individuals with T2DM and NAFLD are needed.